MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
4.890
-0.050
-1.01%
After Hours: 4.860 -0.03 -0.61% 16:21 11/28 EST
OPEN
4.860
PREV CLOSE
4.940
HIGH
4.980
LOW
4.800
VOLUME
1.00M
TURNOVER
0
52 WEEK HIGH
14.73
52 WEEK LOW
4.000
MARKET CAP
396.85M
P/E (TTM)
-4.4825
1D
5D
1M
3M
1Y
5Y
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Karyopharm Therapeutics (KPTI) points to a 96.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indi...
Zacks · 11/08 14:55
Karyopharm Therapeutics upgraded to outperform at RBC on discounted valuation
Seekingalpha · 11/04 14:43
--SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $6 From $5, Maintains Market Perform Rating
--SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $6 From $5, Maintains Market Perform Rating
MT Newswires · 11/04 13:11
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/04 12:56
Under Armour To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Benzinga · 11/04 12:25
Karyopharm surges as blood cancer drug drives sales in Q3, net loss narrows
Seekingalpha · 11/04 10:42
RBC Capital Upgrades Karyopharm Therapeutics to Outperform, Raises Price Target to $10
Benzinga · 11/04 10:15
SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Raises Price Target to $6
Benzinga · 11/04 08:33
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe and the United Kingdom, in combination with dexamethasone to treat adult patients with multiple myeloma.

Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.